We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

69 hedge funds and large institutions have $270M invested in Albireo Pharma Inc in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

38% more funds holding

Funds holding: 50 → 69 (+19)

27% more capital invested

Capital invested by funds: $213M → $270M (+$56.6M)

Holders
69
Holders Change
+19
Holders Change %
+38%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
21
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$14.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$8.95M
3
State Street
State Street
Massachusetts
+$4.54M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$3.49M
5
Northern Trust
Northern Trust
Illinois
+$2.72M

Top Sellers

Rank Fund Capital Flow
1
AWG
Alpha Wave Global
New York
-$5.7M
2
DZ Bank
DZ Bank
Germany
-$2.04M
3
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$1.97M
4
Millennium Management
Millennium Management
New York
-$1.67M
5
AG
Artal Group
Luxembourg
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$60.5M – – –
TGHSA
2
TPG Group Holdings (SBS) Advisors
Texas
$25.4M -$1.97M -60,715 -8%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$22.3M – – –
Federated Hermes
4
Federated Hermes
Pennsylvania
$20.8M +$8.95M +276,221 +89%
BlackRock
5
BlackRock
New York
$18.6M +$14.5M +447,496 +583%
ACH
6
ArrowMark Colorado Holdings
Colorado
$18.2M +$3.49M +107,897 +27%
AG
7
Artal Group
Luxembourg
$17.8M -$1.55M -47,841 -9%
BBA
8
Baker Bros. Advisors
New York
$8.88M – – –
BI
9
BVF Inc
California
$7.81M -$162K -5,000 -2%
SAM
10
Sectoral Asset Management
Quebec, Canada
$6.13M – – –
State Street
11
State Street
Massachusetts
$4.98M +$4.54M +140,312 New
CC
12
Chicago Capital
Illinois
$4.78M +$1.42M +43,917 +48%
Vanguard Group
13
Vanguard Group
Pennsylvania
$4.47M +$1.06M +32,616 +35%
TCM
14
Tekla Capital Management
Massachusetts
$4.44M – – –
HA
15
Heartland Advisors
Wisconsin
$4.44M +$1.09M +33,677 +37%
DM
16
Deerfield Management
New York
$4.26M – – –
Renaissance Technologies
17
Renaissance Technologies
New York
$3.81M +$484K +14,934 +16%
Millennium Management
18
Millennium Management
New York
$3.69M -$1.67M -51,595 -33%
Northern Trust
19
Northern Trust
Illinois
$3.54M +$2.72M +84,053 +533%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$2.89M +$1.09M +33,560 +70%
WMSA
21
Weiss Multi-Strategy Advisers
New York
$1.95M +$648K +20,000 +57%
Victory Capital Management
22
Victory Capital Management
Texas
$1.93M -$101K -3,110 -5%
BC
23
Birchview Capital
Vermont
$1.35M +$453K +14,000 +58%
Allianz Asset Management
24
Allianz Asset Management
Germany
$1.25M +$1.14M +35,214 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.15M +$702K +21,685 +205%
1
2 3 4

ALBO Hedge Fund Activity: Q2 2018 in Review

69 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2018, worth a combined $270M — up 27% from $213M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ALBO positions and 8 closed out — a net gain of 19 holders — while 21 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $14.5M. The largest seller was Alpha Wave Global, exiting entirely with an estimated $5.7M sold.

  • 69 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2018, up from 50 in Q1 2018.
  • Funds reported $270M of Albireo Pharma Inc stock for Q2 2018, up 27% quarter-over-quarter.
  • 27 funds opened new Albireo Pharma Inc positions in Q2 2018 and 8 closed out, a net change of +19 holders.
  • The largest Albireo Pharma Inc buyer in Q2 2018 was BlackRock, an estimated $14.5M added.
  • The largest Albireo Pharma Inc seller in Q2 2018 was Alpha Wave Global, an estimated $5.7M sold.

Based on aggregated 13F filings for Q2 2018.